CSL – Citi rates the stock as Upgrade to Buy from Neutral

With the shares having underperformed the broader market by no less than -19% over the month past, including a noticeable drubbing in yesterday’s session, Citi analysts have upgraded CSL to Buy from Neutral.

The analysts note the global race for a covid-19 vaccine is running in full force now. CSL may or may not get involved with a successful end product, but financial implications should be benign, in case a competitor wins the prize, concludes Citi.

Sector: Pharmaceuticals, Biotechnology & Life Sciences.

Target price is $334.00.Current Price is $288.00. Difference: $46.00 – (brackets indicate current price is over target). If CSL meets the Citi target it will return approximately 14% (excluding dividends, fees and charges – negative figures indicate an expected loss).

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →